Showing 661 - 680 results of 14,795 for search '(( 50 ((nn decrease) OR (mean decrease)) ) OR ( 50 ((ng decrease) OR (we decrease)) ))', query time: 0.63s Refine Results
  1. 661
  2. 662
  3. 663
  4. 664
  5. 665
  6. 666
  7. 667

    Shape-Based Reprofiling of FDA-Approved Drugs for the H<sub>1</sub> Histamine Receptor by Sridhar R. Vasudevan (589877)

    Published 2012
    “…Reprofiling of existing drugs to treat conditions not originally targeted is an attractive means of addressing the problem of a decreasing stream of approved drugs. …”
  8. 668

    Postnatal decrease in PV+ cortical interneurons in Fgfr1 mutant mice. by Karen Müller Smith (613941)

    Published 2014
    “…<p>PV and GFP immunostaining in 8 week old <i>Fgfr1<sup>f/f</sup>;Gad67-GFP+</i> control (<b>A</b>, n = 5) and <i>Fgfr1<sup>f/f</sup>;hGFAP-Cre;Gad67-GFP+</i> mutant mice (<b>B</b>, n = 9). Scale bar is 50 µm in <b>A</b>,<b>B</b>. Stereological analysis show significant decreases in in both GFP and PV immunopositive cells in Fgfr1 mutant mice as compared to littermate controls (<b>C</b>). …”
  9. 669
  10. 670

    Increased claudin-2 expression is not paralled by decreased transepithelial electrical resistance. by Peggy Bodammer (584093)

    Published 2013
    “…<p>Apical stimulation of filter-grown differentiated 14 days postconfluent Caco-2 cells with IL-6 (50 ng/ml) decreased transepithelial electrical resistance (TER) after 24 h compared to unstimulated controls (complete media, CM). …”
  11. 671
  12. 672

    Brivanib decreases viability of PDGF-BB treated LX-2 cells. by Ikuo Nakamura (548298)

    Published 2014
    “…Cells showed a brivanib dose-dependent decrease in viability, with half maximal inhibitory concentration (IC<sub>50</sub>) of 16.98 µM (95% CI 13.95 µM–20.67 µM). …”
  13. 673

    Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

    Published 2024
    “…Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. …”
  14. 674

    Protocol measures. by Sarah E. Maylott (14560785)

    Published 2024
    “…Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. …”
  15. 675

    Cry variables. by Sarah E. Maylott (14560785)

    Published 2024
    “…Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. We propose noninvasive clinical indicators of NOWS, including newborn neurobehavior, autonomic biomarkers, prenatal substance exposures, and socioeconomic environments. …”
  16. 676
  17. 677

    Phosphorylation as an Effective Tool to Improve Stability and Reduce Toxicity of Antimicrobial Peptides by Zufang Ba (11036420)

    Published 2024
    “…Phosphorylation can reduce toxicity and improve the stability of AMPs. Based on these, we designed a series of peptides and their corresponding phosphorylated forms. …”
  18. 678
  19. 679
  20. 680